Completed NCT04524403
This study is completed in the United States. It focuses on schizophrenia.
Multiple locations, including Bentonville Schizophrenia Drug i A study involving a medication or substance. From 18 Years to 65 Years
Countries United States
Sponsor Corcept Therapeutics
Condition Schizophrenia Completed NCT00999895
This summary needs review. Please check the official study record and contact the research team for details.
Multiple locations, including Pátrai Schizophrenia Other From 18 Years to 65 Years
Countries Greece
Sponsor AstraZeneca
Condition Schizophrenia Completed NCT02947308
This study exists to see whether questionnaires and follow-up reports can make care clearer and more responsive. Researchers are trying to understand whether questionnaires and follow-up reports can improve attention, thinking, or day-to-day functioning.
In Minneapolis Suicidality Other From 12 Years to 16 Years
Countries United States
Sponsor University of Minnesota
Condition Suicidality Completed NCT00844857
This summary needs review. Please check the official study record and contact the research team for details.
Multiple locations, including San Diego Bipolarity, Depression Drug From 10 Years to 17 Years
Countries United States, Russia
Sponsor Eli Lilly and Company
Condition Bipolarity, Depression Completed NCT00471354
This summary needs review. Please check the official study record and contact the research team for details.
Multiple locations, including Beijing ADHD Drug From 8 Years to 11 Years
Countries China, South Korea, Taiwan
Sponsor Eli Lilly and Company
Condition ADHD Completed NCT00520923
This summary needs review. Please check the official study record and contact the research team for details.
Multiple locations, including Banfield Schizophrenia Drug From 18 Years to 65 Years
Countries Argentina, Austria, Croatia, ...
Sponsor Eli Lilly and Company
Condition Schizophrenia Completed NCT03629951
This study exists to explore whether this type of care could improve care and understanding. Researchers are trying to understand whether this type of care can better prevent setbacks and support longer-term stability.
Multiple locations, including Ahmedabad Schizophrenia Drug From 18 Years to 50 Years
Countries India
Sponsor Janssen Research & Development, LLC
Condition Schizophrenia Completed NCT00195780
This summary needs review. Please check the official study record and contact the research team for details.
Multiple locations, including San Diego Bipolarity Drug From 10 Years to 17 Years
Countries United States
Sponsor Abbott
Condition Bipolarity Terminated NCT01127646
This summary needs review. Please check the official study record and contact the research team for details.
Multiple locations, including Arnhem ADHD Drug From 6 Years to 16 Years
Countries Netherlands, Spain, Sweden
Sponsor Eli Lilly and Company
Condition ADHD Completed NCT05841030
This study is completed in the United States, in France, in Canada, .... It focuses on depression.
Multiple locations, including Birmingham Depression Other From 18 Years to 74 Years
Countries United States, France, Canada, ...
Sponsor Janssen Research & Development, LLC
Condition Depression Active Not Recruiting NCT03642964
This study is comparing CTC-501 with placebo for people with depression. Participants receive CTC-501 or placebo and complete study visits and assessments.
In Long Beach Depression Drug From 18 Years to 65 Years
Countries United States
Sponsor Chase Therapeutics Corporation
Condition Depression Completed NCT03854578
This study is completed in Germany. It focuses on depression.
In Berlin Depression Drug From 18 Years to 45 Years
Countries Germany
Sponsor Boehringer Ingelheim
Condition Depression